anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to positively charged pro-drugs of NSAIDs represented by the general formula (1, 2a, 2b, 2c or 2d) 'Structure 1, 2a, 2b, 2c or 2 d'. The compounds of the general formula (1, 2a, 2b, 2c or 2d) "structure 1, 2a, 2b, 2c or 2 d" can be prepared by reacting a metal salt or an organic base salt of a non-steroidal anti-inflammatory drug with a suitable halide. The positively charged amino groups in the prodrug greatly increase the solubility of the drug in water and also bind to the negative charge on the phosphate head group of membranes. Thus, the local concentration of the drug outside the membrane or skin can be high, facilitating diffusion of these pro-drugs from areas of high concentration to areas of low concentration. This binding may disturb the membrane slightly to make some room for the liposoluble part of the prodrug. When the molecules of the membrane move, the membrane is slightly squeezed due to the binding of the prodrug. When the amino group is not protonated, the amino group in the prodrug is separated from the phosphate end group of the membrane and the prodrug will be fully incorporated into the membrane.
This study is an open-label, prospective, cross-over randomized study.

VOICE-COVID I: All individuals entering the Heart Failure (HF) Clinic of the McGill University Health Center will be asked to participate. A poster with instructions to ask the participants (employees or patients) to speak with the Amazon Alexa device. The participant will remain 6 feet away from the device. The Amazon Alexa will ask the survey questions. A study coordinator will then ask the same questions along with some additional questions about Amazon Alexa usability. VOICE-COVID II: A second cohort of 52 people will be then randomized to be screened for symptoms of COVID-19 with an Amazon Alexa or a coordinator. We will study the correlation between the Alexa response and the response to the study coordinator using K-squared statistic tests and screening question concordance.
The invention relates to an azilsartan pharmaceutical composition and a preparation method of the pharmaceutical composition. The pharmaceutical composition consists of the raw materials in parts by weight: 20 parts of azilsartan, 60-150 parts of lactose, 30-120 parts of microcrystalline cellulose, 4-10 parts of low substituted hydroxypropyl cellulose, 0.3-2 parts of silicon dioxide and 0.5-5 parts of sodium stearyl fumarate. The pharmaceutical composition is prepared by adopting a direct powder tabletting process. The dissolution rate of over 90 percent can be achieved by adopting a small amount of disintegrating agent, and the pharmaceutical composition has the advantages of high stability and fast disintegration. The preparation method disclosed by the invention is simple in production process, the corresponding equipment plant investment is reduced, and the production cost is saved. The tablets produced by adopting the direct powder tabletting process are fast in disintegration, and dissolution of the medicine is improved. The detection proves that the dissolution rate of the tablets prepared by the method disclosed by the invention is over 90 percent in 30min.
CONSTITUTIVE PHOTOMORPHOGENIC 1 (COP1), a pivotal repressor in plant photomorphogenesis, has been extensively studied in various plant processes. However, the specific roles of COP1 in fruit remain poorly understood. Here, we functionally characterized SlCOP1-1 (also known as LeCOP1), an Arabidopsis (Arabidopsis thaliana) COP1 ortholog, in tomato (Solanum lycopersicum) fruit ripening and disease resistance. Despite the clear upregulation of SlCOP1-1 during fruit ripening, knockout or overexpression (OE) of SlCOP1-1 in tomatoes only minimally affected ripening. Intriguingly, these genetic manipulations substantially altered fruit resistance to the fungal pathogen Botrytis cinerea. Proteomic analysis revealed differential accumulation of proteins associated with fruit disease resistance upon SlCOP1-1 knockout or OE. To unravel the mechanism of SlCOP1-1 in disease resistance, we conducted a screen for SlCOP1-1-interacting proteins and identified the stress-related bZIP transcription factor SlOpaque2. We provide evidence that SlOpaque2 functions in tomato resistance to B. cinerea, and SlCOP1-1-mediated mono-ubiquitination and stabilization of SlOpaque2 contributes to fruit resistance against B. cinerea. Our findings uncover a regulatory role of COP1 in controlling fruit disease resistance, enriching our understanding of the regulatory network orchestrating fruit responses to disease.
The proteins carried by the extracellular vesicles of Lactobacillus salivarius SNK-6 (LsEVs) were identified to provide a foundation for further explorations of the probiotic activities of L. salivarius SNK-6. LsEVs were isolated from the culture media of L. salivarius SNK-6 and morphological analysis was conducted by scanning electron microscopy. Subsequent transmission electron microscopy and nanoparticle tracking analysis were performed to assess the morphology and particle size of the LsEVs. In addition, the protein composition of LsEVs was analyzed using silver staining and protein mass spectrometry. Finally, internalization of the identified LsEVs was confirmed using a confocal microscope, and enzyme-linked immunosorbent assay was employed to analyze the levels of inflammatory cytokines in LPS-challenged RAW264.7 cells. The results revealed that the membrane-enclosed LsEVs were spherical, with diameters ranging from 100-250 nm. The LsEVs with diameters of 111-256 nm contained the greatest amount of cargo. In total, 320 proteins (10-38 kD) were identified in the LsEVs and included anti-inflammatory molecules, such as PrtP proteinase, co-chaperones, and elongation factor Tu, as well as some proteins involved in glycolysis/gluconeogenesis, such as fructose-1,6-bisphosphate aldolase. Enrichment analysis showed these proteins to be related to the terms "metabolic pathway," "ribosome," "glycolysis/gluconeogenesis," "carbohydrate metabolism," and "amino acid metabolism." Furthermore, the LsEVs were internalized by host liver cells and can regulate inflammation. These findings confirm that LsEVs contain various functional proteins that play important roles in energy metabolism, signal transduction, and biosynthesis.
Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
Multitargeting has become a promising strategy for the development of anti-Alzheimer's disease (AD) drugs, considering the complexity of molecular mechanisms in AD pathology. In most pre-clinical studies, the effectiveness of these multi-targeted anti-AD drugs has been demonstrated but comprehensive safety assessments are lacking. Here, the safety evaluation of a novel multi-targeted candidate in AD (XYY-CP1106), characterized by its dual-property of iron chelation and monoamine oxidase B inhibition, was conducted by multifaceted analysis. Acute toxicity in mice was conducted to investigate the safety of oral administration and the maximum tolerated dose of the agent. In vitro Ames analysis, CHL chromosomal aberration analysis, and bone marrow micronucleus analysis were executed to evaluate the genotoxicity. A teratogenesis investigation in pregnant mice were meticulously performed to evaluate the teratogenesis of XYY-CP1106. Furthermore, a 90-day long-term toxicity analysis in rats was investigated to evaluate the cumulative toxicity after long-term administration. Strikingly, no toxic phenomena were found in all investigations, demonstrating relatively high safety profile of the candidate compound. The securing of safety heightened the translational significance of XYY-CP1106 as a novel multi-targeted anti-AD candidate, supporting the rationality of multitargeting strategy in the designs of smart anti-AD drugs.
Endoscopic methods are frequently used in the diagnosis of gastrointestinal system pathologies in children. In the investigators' center, which is a pandemic hospital, only emergency endoscopic procedures were performed during the pandemic period, while emergency and elective endoscopic procedures are performed in accordance with the recommendations of the Ministry of Health during the normalization process. Staff and patients in endoscopy units are at risk for COVID-19 infection by inhalation of airborne droplets, conjunctival contact, and potential fecal-oral contamination. In order to reduce the risk of contamination, according to the recommendations of the European Gastrointestinal Endoscopy Association (ESGE); proper cleaning of endoscopic devices, non-reuse of disposable devices, cleaning the endoscopy hall with a disinfectant solution, use of gowns FFP2 / 3 masks and jewelry during the procedure, handwashing with soap and hand disinfection is recommended before and after each procedure. In addition, it is recommended that patients who have undergone endoscopic procedures should be followed up or communicated on days 7 and 14 in terms of the development of COVID-19 infection.

It is recommended that patients should be questioned in terms of COVID-19 infection before endoscopy, but rapid antigen testing and serology are not routinely recommended. Molecular diagnosis (PCR, amplification) tests are recommended for patients at risk for COVID-19 infection.
BACKGROUND: Few studies have investigated intravenous lacosamide use to treat cluster seizures in pediatric patients. Therefore, we aimed to investigate the efficacy and safety of intravenous lacosamide therapy in pediatric patients with cluster seizures.
METHODS: We retrospectively evaluated the efficacy and safety of intravenous lacosamide therapy in 25 pediatric patients with cluster seizures at Saitama Children's Medical Center between March 2019 and June 2023. Cluster seizures were defined as a single seizure of less than five minutes duration, repeated three or more times within 12 hours, with recovery of consciousness between seizures. Response was defined as seizure freedom for at least 12 hours after lacosamide infusion.
RESULTS: The median age at onset of epilepsy was 1.5 (0.0 to 9.8) years. The median seizure frequency was 5 (3 to 20) times per 12 hours. The etiologies were remote (n = 17), acute (n = 4), and progressive (n = 4). The median age at which intravenous lacosamide therapy was administered was 4.2 (0.0 to 11.3) years. The median lacosamide dose was 2.6 (1.3 to 5.2) mg/kg. In total, 12 of 25 patients (48.0%) responded. Among patients treated with intravenous lacosamide as first-line therapy, nine of 17 (52.9%) had complete seizure remission. The frequency of complete seizure remission in patients with remote etiologies was 58.8% (10 of 17); among them, seven of 12 (58.3%) patients with structural abnormalities showed complete seizure remission. No adverse events were observed.
CONCLUSIONS: Intravenous lacosamide therapy is a potentially useful treatment option for cluster seizures in pediatric patients.
FIELD: organic chemistry. SUBSTANCE: product: derivatives of benzimidazole of the formula I at the corresponding radical values R 1 - R 3 , and a method of their synthesis by interaction of compound of the formula II with compound R′-Y. Synthesized compounds were used in pharmacology. Structure of compounds of the formulas I and II is given in invention description. EFFECT: improved method of synthesis. 42 cl
BACKGROUND: Socioeconomic status (SES) affects outcomes following surgery for various cancers. There are currently no Australian studies that examine the role of socioeconomic disadvantage on outcomes following oesophagectomy for cancer. This study assessed whether SES was associated with short-term perioperative morbidity, long-term survival, and oncological outcomes following oesophagectomy across three tertiary oesophageal cancer centres in Australia.
METHODS: A retrospective cohort study was performed comprising all patients who underwent oesophagectomy for cancer across three Australian centres. Patients were stratified into SES groups using the Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD). Outcomes measured included perioperative complication rates, overall survival, and disease-free survival.
RESULTS: The study cohort was 462 patients, 205 in the lower SES and 257 in the higher SES groups. The lower SES group presented with more advanced oesophageal cancer stage, a higher rate of T3 (52.6% versus 42.7%, P = 0.038) and N2 disease (19.6% versus 10.5%, P = 0.006), and had a higher rate of readmission within 30 days (11.2% versus 5.4%, P = 0.023). There was no difference in overall survival or disease-free survival between groups.
CONCLUSION: Lower socioeconomic status was associated with more advanced stage and increased risk of early, unplanned readmission following oesophagectomy, but was not associated with a difference in overall or disease-free survival.
Few population-based studies including younger adults have examined the potential of olfactory function tests to capture the degree of atrophy in memory-associated brain regions, which cannot be adequately explained by cognitive function tests screening for cognitive impairment. This population-based study investigated associations between high-resolution olfactory test data with few odours and grey matter volumes (GMVs) of the left and right hippocampi, amygdala, parahippocampi, and olfactory cortex, while accounting for differences in cognitive decline, in 1444 participants (aged 31-91 years). Regression analyses included intracranial volume (ICV)-normalised GMVs of eight memory-related regions as objective variables and age, sex, education duration, smoking history, olfaction test score, and the Montreal Cognitive Assessment-Japanese version (MoCA-J) score as explanatory variables. Significant relationships were found between olfactory test scores and ICV-normalised GMVs of the left and right hippocampi and left amygdala (p = 0.020, 0.024, and 0.028, respectively), adjusting for the MoCA-J score. The olfactory test score was significantly related to the right amygdalar GMV (p = 0.020) in older adults (age ≥ 65 years). These associations remained significant after applying Benjamini-Hochberg multiple testing correction (false discovery rate < 0.1). Therefore, olfactory and cognitive function tests may efficiently capture the degree of atrophy in the hippocampi and amygdala, especially in older adults.
1,128,130. Alkaloids; tenuazonic acid. INSTITUT NATIONAL DE RECHERCHE CHIMIQUE APPLIQUEE. 8 March, 1967 [15 March, 1966], No. 10928/67. Headings C2C and C2G. [Also in Division C6] In order to increase their yield of extractable alkaloids, poppies prior to any alkaloid extraction treatment operations, are caused to ferment by means of micro-organisms applied thereto, particularly of the species Alternaria tenuissima, Alternaria chartorum or a variety designated Alternaria Pl, all isolated from capsules of poppies naturally contaminated by mould. The isolated moulds may be cultivated and maintained in a medium consisting chiefly of poppy powder, kept in suspended animation in a medium having a reduced proportion of nutrient substances, or lyophilized. Crushed, sterilized and humidified poppies, particularly those of the species Papaverum album or Papaverum nigrum, are submitted to aerobic fermentation conditions while immersed in water, at a temperature ranging from 5‹ to 40‹ C. for a period of from one day to one month. The resulting fermentation product is subjected to alkaline extractions with chloroform, benzene and isobutanol followed by an acid extraction with chloroform. Small amounts of tenuazonic acid and other non-alkaloid substances are recovered by the acid extraction. In an alternative extraction procedure, the fermentation product is macerated twice in water and then in hydrochloric acid. The filtrate is rendered alkaline by ammonia to pH 9 and extracted with 3: 1 chloroform and isobutanol. The dry residue obtained by evaporating the solvent, is redissolved in chloroform and the alkaloid bases are extracted from this chloroform solution using a solution containing 2À33% by weight of hydrochloric acid. The acid-aqueous phase is then washed with chloroform, whereby the alkaloid bases of the isoquinolinic constituents (noscapine and papaverine) can be extracted from the organic phase. The acid aqueous extract free of alkaloids removed by the chloroform, is rendered alkaline by ammonia to pH 9 and this basic aqueous solution is then washed with 3: 1 chloroform and isobutanol, whereby the alkaloid bases of the phenanthrenic compounds (morphine and codeine) can be extracted from the organic phase.
A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single organic solvent, and the steps are completed at temperatures below 100Â°C. The exclusion of chloride ions, of chloride free-radicals, hypochlorite ions, or hypochlorous acid as reagents or from reagents that may generate these species in situ in the presence of oxidants, prevents undesirable impurity formation. Several new compounds have been conceived and isolated using these methods. These new compounds are also formed into new medicaments.
The invention belongs to the technical field of medicine, and particularly relates to a compound Chinese patent drug for treating a primary liver cancer, and an administration method of the compound Chinese patent drug. The primary liver cancer is one of the common malignant tumors in China. The compound Chinese patent drug adopts 13 medicinal materials for compounding, can eliminate pathogens, strengthen body resistance, promote blood circulation, stop bleeding and treat a liver and a spleen, and treats the primary liver cancer by integrating external treatment and internal treatment. The compound Chinese patent drug adopts the technical scheme that the following medicinal materials and matching ratio are adopted, and the 13 medicinal materials are porphyrized and uniformly mixed into powder according to the matching ratio. The 1.5-2g liver benefiting powder is taken directly with warm water at each time for 2-3 times per day. External application treatment is conducted as follows: realgar is placed in an abdomen of a live toad (with viscera being removed), warm water is added to prepare paste, and then the toad is externally applied at a hepatic region for twice per day.
FIELD: medicine, biochemistry. SUBSTANCE: invention relates to agents correcting disturbances in metabolism. An agent has succinic acid or its pharmaceutically acceptable salt and substances showing vitamin effect, for example, vitamins A, C, D, E, folic acid, vitamins of the group B and if necessary pharmaceutically acceptable carrier at the following ratio of components, wt. -%: succinic acid up to 99.998; substances showing vitamin effect - the rest. EFFECT: enhanced effectiveness of the agent. 3 cl, 7 tbl, 7 ex
An aqueous cosmetic preparation for coloring of eyelids and eyebrows contains 3-35 wt. % of an aqueous plastic dispersion based on an acrylate polymer and having a 30-50% solids content, 1-20 wt. % of at least one alcohol being ethanol and/or propanol, 2-25 wt. % of at least one moisture-retention agent, 0.2-5 wt. % of a polyoxyethylene glycerin fatty acid ester and/or a polyether-modified polysiloxane, and a colorant. The preparation has a Brookfield viscosity at 25 DEG C. of less than 50 mPa-sec.
An improved dietary supplement for mammals, the dietary supplement including the essential dietary trace metals, iron, copper and molybdenum. These metals are provided in a highly bioavailable state such as peptide and polypeptide chelates. This invention also includes a method for using natural proteinaceous starting materials for producing the peptide and polypeptide ligands for the chelates. The proteinaceous starting materials are obtained from a primary grown yeast, an isolated vegetable protein, dessicated tissues of animal origin and the like which, upon hydrolysis, yields the peptide and polypeptide ligands suitable for forming chelates with the iron, copper and molybdenum. The metals are each separately chelated with the peptide and polypeptide ligands and thereafter combined in the suitable ratios to form the dietary supplement. The dietary supplement is adsorbed on a suitable food product and provided in an effective amount for consumption in iron deficiency anemia.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other imiglucerase products may be misleading.

Approximately 15% of patients treated and tested to date have developed IgG antibody to Cerezyme during the first year of therapy. Patients who developed IgG antibody did so largely within 6 months of treatment and rarely developed antibodies to Cerezyme after 12 months of therapy. Approximately 46% of patients with detectable IgG antibodies experienced symptoms of hypersensitivity. Patients with antibody to Cerezyme have higher risk of hypersensitivity reaction [see Warnings and Precautions (5.1)]. Patients who developed IgG antibody to Cerezyme had increased elimination half-life compared to patients without antibody [see Clinical Pharmacology (12.3)].
Hyperammonemia is a serious clinical condition associated with significant morbidity and mortality. In the pediatric population, this is often caused by urea cycle disorders, acute liver failure, or other less common underlying etiologies. Children and teens with hyperammonemia can have a broad range of clinical findings, including vomiting, respiratory distress, and changes in mental status. As ammonia levels worsen, this presentation can progress to respiratory failure, encephalopathy, cerebral edema, seizures, and death. Given the risk of neurologic damage, timely identification and management of hyperammonemia is critical and includes initial resuscitation, early consultation with subspecialists, and initiation of appropriate therapies. It is important for pediatric emergency medicine providers to understand the clinical findings, causes, diagnosis, and management of hyperammonemia because they play a key role in the provision of effective, multidisciplinary care of these patients.
The invention relates to an antitumor composition based on hydrophobized hyaluronan and inorganic nanoparticles stabilized by oleic acid. The hydrophobized hyaluronan in the form of an acylated hyaluronan serves in the composition as a carrier of inorganic nanoparticles. Out of the group of inorganic nanoparticles, the composition may comprise superparamagnetic nanoparticles, nanoparticles of ZnO and moreover, upconversion nanoparticles. Said composition is selectively cytotoxic with respect to both suspension and adherent tumor cell lines, especially with respect to tumor cell lines of colorectum carcinoma and adenocarcinoma, lung carcinoma, hepatocellular carcinoma and breast adenocarcinoma. The highest cytotoxic effects were observed in case of the composition based on an oleyl derivative of hyaluronan with SPIONs. The composition of acylated hyaluronan with SPIONs may also be advantageously used for an in vivo detection of accumulation of the composition in the body, preferably in a tumor or in liver. Said composition is sterilizable in the final package.